Experimental and Clinical Psychopharmacology seeks to promote the discipline of psychopharmacology in its fullest diversity. Psychopharmacology necessarily involves behavioral change, psychological processes, or their physiological substrates as one central variable and psychopharmacological agents as a second central variable. Such agents will include drugs, medications, and chemicals encountered in the workplace or environment. One goal of the journal is to foster basic research and the development of theory in psychopharmacology. Another is to encourage the integration of basic and applied research, the development of better treatments for drug abuse, and more effective pharmacotherapeutics. To this end, the journal publishes original empirical research involving animals or humans that spans (a) behavioral pharmacology research on social, behavioral, cognitive, emotional, physiological, and neurochemical toxicity; (b) descriptive and experimental studies of drug abuse, including its etiology, progression, adverse effects, and behavioral and pharmacological treatment; and (c) controlled clinical trials that, in addition to improving the effectiveness, range, or depth of application, will increase our understanding of psychological functions or their drug modulation. The journal also publishes theoretical and integrative analyses and reviews that promote our understanding and further systematic research in psychopharmacology. The journal also publishes papers in two other sections, Innovations and Remarks. Innovations is an occasional section that will highlight papers that establish a novel method, a novel result, a novel measure, or a new theory. Commentary may be solicited to address the nature of the innovation and to provide contrasting views. Remarks is another occasional section. The purpose of "remarks" is for brief commentary about important aspects of the field that have not been previously addressed or considered. Remarks could address either empirical or theoretical issues. Remarks are expected to be erudite, integrative, substantive, and thoughtful. Although case studies are not appropriate, occasional small sample experiments with special populations may be considered. The journal is intended to be informative and useful to both basic and applied researchers and to practitioners operating in varied settings. Experimental and Clinical Psychopharmacology seeks to be the vehicle for the best research ideas and for integrating pharmacology and behavior.

實驗和臨床精神藥理學旨在促進精神藥理學學科的最大多樣性。心理藥理學必然涉及行為變化、心理過程或其生理底物作為一個中心變量，心理藥理學藥物作為第二個中心變量。這些藥劑包括在工作場所或環境中遇到的藥物、藥物和化學品。該雜志的一個目標是促進基礎研究和心理藥理學理論的發展。另一個是鼓勵基礎研究和應用研究相結合，開發更好的藥物濫用治療方法，以及更有效的藥物治療。為此，該雜志發表了涉及動物或人類的原始實驗研究，涵蓋（a）社會、行為、認知、情感、生理和神經化學毒性的行為藥理學研究；（b）藥物濫用的描述性和實驗研究，包括其病因、進展、不良反應和行為和藥物治療；（c）對照臨床試驗，除了提高有效性、應用范圍或深度外，還將增加我們對心理功能或藥物調節的理解。該雜志還發表了理論和綜合分析和評論，以促進我們的理解和進一步的心理藥理學系統研究。該雜志還出版了其他兩個部分的論文：創新和評論。創新是一個偶然的部分，它將強調建立一種新方法、新結果、新措施或新理論的論文。可以征求評論來說明創新的性質，并提供對比意見。評論是另一個偶然的部分?！霸u論”的目的是對該領域的重要方面進行簡短的評論，而這些方面此前尚未得到討論或考慮。評論可以解決經驗或理論問題。預計發言將是博學的、綜合的、實質性的和深思熟慮的。雖然案例研究不合適，但偶爾也可以考慮對特殊人群進行小樣本實驗。該雜志旨在為基礎和應用研究人員以及在不同環境下工作的從業者提供信息和有用。實驗和臨床精神藥理學尋求成為最佳研究思想和整合藥理學和行為的載體。